Prolight Diagnostics

Prolight has received notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application concerning the analytical device and reaction chamber for the company’s point-of-care system MicroFlex, in development by Prolight’s partner TTP (The Technology Partnership plc).
 
The notice of allowance from USPTO means that the patent application is intended to be approved in the USA after certain formal steps are completed. Once granted, the patent will be in effect until May 2040.
 
The patent, once granted, provides protection for the unique technical composition of the MicroFlex’s analytical device and reaction chamber.
 
“The patent is a testament to the technological height of MicroFlex. We are certain that it will add to MicroFlex’s competitive position and that TTP will make good use of it,” said Ulf Bladin, CEO of Prolight.